Quality of life, treatment impact and duration, and the importance of individualized therapy are at the center of ...

Women whose breast cancers need estrogen to grow are often treated for five or more years with medications to lower estrogen ...

An enzyme called cyclin-dependent kinase 2 (CDK2) regulates the cell cycle and may have the potential to drive therapeutic ...

When prostate cancer patients need therapy to reduce male hormone levels, delivering some of the treatment via a patch on the ...

Barry Goy, MD, provides insight into the clinical implications of a retrospective analysis examining 15-year outcomes in patients with intermediate-risk prostate cancer.

Responses were similar among patients with estrogen patches and ARPIs compared to luteinizing hormone releasing hormone ...

Researchers analyzed data on 215 women diagnosed with stages 0-III breast cancer between January 2000 and October 2024 who ...

A paper inadvertently published on the website of an ASCO conference revealed good results for mevrometostat in treating ...

Swedish biotech company Gesynta Pharma AB has secured $27 million in a Series B financing round led by Innovestor Life Science in Finland.

Real-world data highlight gaps in genetic testing and targeted therapy use for metastatic castration-resistant prostate ...